Yavuz BEYAZIT, Murat KEKİLLİ, Ece ÜNAL ÇETİN, Fatih KAMIŞ, Adil Ugur ÇETİN

Serum chitotriosidase and YKL-40 in acute pancreatitis: Reliability as prognostic marker for disease severity and correlation with inflammatory markers

Background/aim: Chitotriosidase and YKL-40, also called chitinase 3-like protein 1, are homologs of family 18 glycosyl hydrolases, secreted by human macrophages and granulocytes under inflammatory conditions. Although increased levels of chitotriosidase and YKL-40 are linked with several inflammatory diseases, the physiological utility of these two enzymes is still not fully characterized. This study aims to analyse the serum YKL-40 and chitotriosidase levels of acute pancreatitis patients to assess whether their activity correlates with acute pancreatitis and its severity. Materials and methods: Chitotriosidase and YKL-40 levels, along with routine laboratory parameters, were determined from the serum samples of 41 acute pancreatitis patients, at both onset and remission (male/female: 22/19), and 39 healthy subjects (male/female: 19/20). The Modified Glasgow Prognostic Score was used to predict the severity of the disease, and a correlation analysis was performed between study variables. Results: A statistically significant increase in both chitotriosidase and YKL-40 levels was observed in acute pancreatitis patients compared to healthy controls (P < 0.001). Higher levels of YKL-40, chitotriosidase and C-reactive protein were found in patients with acute pancreatitis at onset than in remission. The correlation analysis showed a statistically significant association between YKL-40 and chitotriosidase (p = 0.039, r = 0.323). The cut-off point for YKL-40, for detecting acute pancreatitis, was 60.3 with a sensitivity and specificity of 84.9% and 84.6% (AUC: 0.890). The optimum cut-off points for chitotriosidase, for detecting acute pancreatitis, was 33.5 with a sensitivity and specificity of 79.5% and 78.4% (AUC: 0.899). Conclusion: Elevated YKL-40 and chitotriosidase levels in acute pancreatitis patients demonstrate the importance of possible macrophage involvement in the pancreatic microenvironment during acute pancreatitis progression.Key words: Acute pancreatitis, YKL-40, chitotriosidase, inflammation

PDF

___

1. Sayilir A, Beyazit Y, Yesil Y, Albayrak M, Ekiz F et al. Plasma thrombin-activatable fibrinolysis inhibitor as an indicator of inflammation and disease severity in acute pancreatitis. Clinics and Research in Hepatology and Gastroenterology 2012; 36 (5): 498-505. doi: 10.1016/j.clinre.2011.12.006
2. Beyazit Y, Sayilir A, Torun S, Suvak B, Yesil Y et al. Mean platelet volume as an indicator of disease severity in patients with acute pancreatitis. Clinics and Research in Hepatology and Gastroenterology 2012; 36 (2): 162-168. doi: 10.1016/j. clinre.2011.10.003
3. Neoptolemos JP, Kemppainen EA, Mayer JM, Fitzpatrick JM, Raraty MG et al. Early prediction of severity in acute pancreatitis by urinary trypsinogen activation peptide: a multicentre study. Lancet 2000; 355 (9219): 1955-1960. doi: 10.1016/s0140-6736(00)02327-8
4. Yasuda H, Kataoka K, Takeyama Y, Takeda K, Ito T et al. Usefulness of urinary trypsinogen-2 and trypsinogen activation peptide in acute pancreatitis: A multicenter study in Japan. World Journal of Gastroenterology 2019; 25 (1): 107- 117. doi: 10.3748/wjg.v25.i1.107
5. Chatterjee R, Parab N, Sajjan B, Nagar VS. Comparison of Acute Physiology and Chronic Health Evaluation II, Modified Computed Tomography Severity Index, and Bedside Index for Severity in Acute Pancreatitis Score in Predicting the Severity of Acute Pancreatitis. Indian Journal of Critical Care Medicine 2020; 24 (2): 99-103. doi: 10.5005/jp-journals-10071-23343
6. Majewski S, Tworek D, Szewczyk K, Kiszałkiewicz J, Kurmanowska Z et al. Overexpression of chitotriosidase and YKL-40 in peripheral blood and sputum of healthy smokers and patients with chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 2019; 14: 1611-1631. doi: 10.2147/COPD.S184097
7. Musumeci M, Caruso V, Medulla E, Torrisi V, Migale R et al. Serum YKL-40 levels and chitotriosidase activity in patients with beta-thalassemia major. Disease Markers 2014; 2014: 965971. doi: 10.1155/2014/965971
8. Żurawska-Płaksej E, Ługowska A, Hetmańczyk K, KnapikKordecka M, Adamiec R et al. Proteins from the 18 glycosyl hydrolase family are associated with kidney dysfunction in patients with diabetes type 2. Biomarkers 2015; 20 (1): 52-57. doi: 10.3109/1354750X.2014.992475
9. Bennett D, Cameli P, Lanzarone N, Carobene L, Bianchi N et al. Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis. Respiratory Research 2020; 21 (1): 6. doi:
10.1186/s12931-019-1263-z 10. Bustamante A, Dominguez C, Rodriguez-Sureda V, Vilches A, Penalba A, Giralt D et al. Prognostic value of plasma chitotriosidase activity in acute stroke patients. International Journal of Stroke 2014; 9 (7): 910-916. doi: 10.1111/ijs.12160
11. Gunay AE, Karaman I, Karaman ZF, Kocer D, Dogan S et al. Relationship Between Serum YKL-40 Level and Forearm Arterial Patency After Repair. Annals of Vascular Surgery 2021; 74: 301-305. doi: 10.1016/j.avsg.2020.12.018
12. Matsumoto T, Tsurumoto T. Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laborarory parameters. Clinical and Experimental Rheumatology 2001; 19 (6): 655-660.
13. Väänänen T, Koskinen A, Paukkeri EL, Hämäläinen M, Moilanen T et al. YKL-40 as a novel factor associated with inflammation and catabolic mechanisms in osteoarthritic joints. Mediators of Inflammation 2014; 2014: 215140. doi: 10.1155/2014/215140
14. Luo W, Zhang L, Sheng L, Zhang Z, Yang Z. Increased levels of YKL-40 in patients with diabetes mellitus: a systematic review and meta-analysis. Diabetology & Metabolic Syndrome 2021; 13 (1): 6. doi: 10.1186/s13098-021-00624-9
15. Dichev V, Mehterov NH, Kazakova MH, Karalilova RV, Batalov AZ et al. Serum protein levels of YKL-40 and plasma miR214 expression in patients with systemic sclerosis. Modern Rheumatology 2021: 1-13. doi: 10.1080/14397595.2020.1859726
16. Roslind A, Palle C, Johansen JS, Christensen IJ, Nielsen HJ et al. Prognostic utility of serum YKL-40 in patients with cervical cancer. Scandinavian Journal of Clinical Laboratory Investigation 2020; 80 (8): 687-693. doi: 10.1080/00365513.2020.1846209
17. Xing Y, Guo J, Gai L, Liu B, Luo D. Serum YKL-40 is associated with the severity of coronary artery disease and hypertension. Asian Journal of Surgery 2020; 43 (11): 1121-1122. doi: 10.1016/j.asjsur.2020.08.016
18. Khashaba SA, Attwa E, Said N, Ahmed S, Khattab F. Serum YKL-40 and IL 17 in Psoriasis: Reliability as prognostic markers for disease severity and responsiveness to treatment. Dermatology and Therapy 2020: e14606. doi: 10.1111/ dth.14606
19. Johansen JS, Floyd AK, Christensen IJ, Modrau IS, ThorlaciusUssing O. Serum YKL-40 in Patients with Acute Pancreatitis. Journal of Autoimmunity & Research 2016; 3 (2): 1013.
20. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG et al. Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013; 62 (1): 102-111. doi: 10.1136/ gutjnl-2012-302779
21. Blamey SL, Imrie CW, O’Neill J, Gilmour WH, Carter DC. Prognostic factors in acute pancreatitis. Gut 1984; 25 (12): 1340-1346.doi: 10.1136/gut.25.12.1340
22. Gezer NS, Bengi G, Baran A, Erkmen PE, Topalak ÖS et al. Comparison of radiological scoring systems, clinical scores, neutrophil-lymphocyte ratio and serum C-reactive protein level for severity and mortality in acute pancreatitis. Revista de Associacao Medica Brasileira (1992) 2020; 66 (6): 762-770. doi: 10.1590/1806-9282.66.6.762
23. Krecak I, Gveric-Krecak V, Roncevic P, Basic-Kinda S, Gulin J et al. Serum chitotriosidase: a circulating biomarker in polycythemia vera. Hematology 2018; 23 (10): 793-802. doi: 10.1080/10245332.2018.1498157
24. Hu F, Lou N, Jiao J, Guo F, Xiang H et al. Macrophages in pancreatitis: Mechanisms and therapeutic potential. Biomedicine & Pharmacotherapy 2020; 131: 110693. doi: 10.1016/j.biopha.2020.110693
25. Tasci C, Tapan S, Ozkaya S, Demirer E, Deniz O et al. Efficacy of serum chitotriosidase activity in early treatment of patients with active tuberculosis and a negative sputum smear. Therapeutics and Clinical Risk Management 2012; 8: 369-372. doi: 10.2147/TCRM.S31752
26. Fujisawa T, Hozumi H, Yasui H, Suzuki Y, Karayama M et al. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease. The Journal of Rheumatology 2019; 46 (8): 935-942. doi: 10.3899/jrheum.180825
27. Barone R, Simporé J, Malaguarnera L, Pignatelli S, Musumeci S. Plasma chitotriosidase activity in acute Plasmodium falciparum malaria. Clinica Chimica Acta 2003; 331 (1-2): 79- 85. doi: 10.1016/s0009-8981(03)00089-5
28. Kucur M, Isman FK, Balci C, Onal B, Hacibekiroglu M et al. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia. Urologic Oncology 2008; 26 (1): 47-52. doi: 10.1016/j.urolonc.2007.07.020
29. Khashaba SA, Attwa E, Said N, Ahmed S, Khattab F. Serum YKL-40 and IL 17 in Psoriasis: Reliability as prognostic markers for disease severity and responsiveness to treatment. Dermatology and Therapy 2020: e14606. doi: 10.1111/ dth.14606
30. Chen IM, Johansen AZ, Dehlendorff C, Jensen BV, Bojesen SE et al. Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer. Cancer Epidemiology, Biomarkers & Prevention 2020; 29 (1): 176-184. doi: 10.1158/1055-9965
31. Imamura T, Tanaka S, Yoshida H, Kitamura K, Ikegami A et al. Significance of measurement of high-sensitivity C-reactive protein in acute pancreatitis. Journal of Gastroenterology 2002; 37 (11): 935-938. doi: 10.1007/s005350200157
32. Al-Bahrani AZ, Ammori BJ. Clinical laboratory assessment of acute pancreatitis. Clinica Chimica Acta 2005; 362 (1-2): 26- 48. doi: 10.1016/j.cccn.2005.06.008
33. Andreassen M, Vestergaard H, Kristensen LØ. Concentrations of the acute phase reactants high-sensitive C-reactive protein and YKL-40 and of interleukin-6 before and after treatment in patients with acromegaly and growth hormone deficiency. Clinical Endocrinology (Oxford) 2007; 67 (6): 909-916. doi: 10.1111/j.1365-2265.2007.02986.x
34. Erturk A, Cure E, Cure MC, Parlak E, Kurt A et al. The association between serum YKL-40 levels, mean platelet volume, and c-reactive protein in patients with cellulitis. Indian Journal of Medical Microbiology 2015; 33: 61-66. doi: 10.4103/0255-0857.150891
35. Johansen JS, Krabbe KS, Møller K, Pedersen BK. Circulating YKL-40 levels during human endotoxaemia. Clinical & Experimental Immunology 2005; 140 (2): 343-348. doi: 10.1111/j.1365-2249.2005.02763.x
36. Rehli M, Niller HH, Ammon C, Langmann S, Schwarzfischer L et al. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. Journal of Biological Chemistry 2003; 278 (45): 44058-44067. doi: 10.1074/jbc. M306792200